<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LAMIVUDINEÂ - lamivudineÂ tablet, film coatedÂ </strong><br>Aurobindo Pharma Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.<br><br>LAMIVUDINE tablets for oral use<br>Initial U.S. Approval: 1995</div>
<div class="Warning"><div>
<br><h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, POSTTREATMENT EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B IN CO-INFECTED PATIENTS, DIFFERENT FORMULATIONS OF LAMIVUDINE</span><br><span class="Bold"><span class="Italics"><br>See full prescribing information for complete boxed warning</span></span>
</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">Â  </span></span></h1>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including </span><span class="Bold">fatal cases, have been reported with the use of nucleoside analogues. </span><span class="Bold">Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. <a href="#Section_5.1">(5.1)</a></span>
</li>
<li><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. <a href="#Section_5.2">(5.2)</a></span></li>
<li>
<span class="Bold">Patients with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should receive only dosage forms of lamivudine</span><span class="Bold"> appropriate for treatment of HIV-1. <a href="#Section_5.2">(5.2)</a></span>
</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<br><h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, POSTTREATMENT EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B IN CO-INFECTED PATIENTS, DIFFERENT FORMULATIONS OF LAMIVUDINE</span><br><span class="Bold"><span class="Italics"><br>See full prescribing information for complete boxed warning</span></span>
</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">Â  </span></span></h1>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including </span><span class="Bold">fatal cases, have been reported with the use of nucleoside analogues. </span><span class="Bold">Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. <a href="#Section_5.1">(5.1)</a></span>
</li>
<li><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. <a href="#Section_5.2">(5.2)</a></span></li>
<li>
<span class="Bold">Patients with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should receive only dosage forms of lamivudine</span><span class="Bold"> appropriate for treatment of HIV-1. <a href="#Section_5.2">(5.2)</a></span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br><p class="Highlighta">Lamivudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Limitation of Use: The dosage of this product is for HIV-1 and not for HBV. <a href="#Section_1">(1)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. <a href="#Section_2.1">(2.1)</a>
</li>
<li>Pediatric Patients Aged 3 Months and Older: Administered twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. <a href="#Section_2.2">(2.2)</a>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Doses of lamivudine tablets must be adjusted in accordance with renal function. <a href="#Section_2.3">(2.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Tablets: 300 mg <a href="#Section_3">(3)</a>
</li>
<li>Tablets: 150 mg scored <a href="#Section_3">(3)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<br><p class="Highlighta">Lamivudine tablets are contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any of the components of the products. <a href="#Section_4">(4)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis: Reported with the use of nucleoside analogues. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. <a href="#Section_5.1">(5.1)</a>
</li>
<li>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>: Reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus and HIV-1 and discontinued lamivudine. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Patients with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should receive only dosage forms of lamivudine appropriate for treatment of HIV-1. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Co-infected HIV-1/HBV Patients: Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Emtricitabine should not be administered concomitantly with lamivudine-containing products. <a href="#Section_5.3">(5.3)</a>
</li>
<li>Hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving interferon and ribavirin-based regimens. Monitor for treatment-associated toxicities. Discontinue lamivudine as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. <a href="#Section_5.4">(5.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>: Use with caution in pediatric patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or other significant risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Discontinue treatment as clinically appropriate. <a href="#Section_5.5">(5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <a href="#Section_5.6">(5.6)</a> and redistribution/accumulation of body fat <a href="#Section_5.7">(5.7)</a> have been reported in patients treated with combination antiretroviral therapy.</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>The most common reported adverse reactions (incidence greater than or equal to 15%) in adults were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, nasal signs and symptoms, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. <a href="#Section_6.1">(6.1)</a>
</li>
<li>The most common reported adverse reactions (incidence greater than or equal to 15%) in pediatricÂ subjects were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. (<a href="#Section_6.2">6.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br><p class="Highlighta">Zalcitabine is not recommended for use in combination with lamivudine. <a href="#Section_7.2">(7.2)</a> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc"><li>Lactation: Breastfeeding not recommended. (<a href="#Section_8.2">8.2</a>)</li></ul>
<p class="Highlighta"><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Companyâ€™s EPIVIR<span class="Sup">Â®</span> (lamivudine) tablets. However, due to ViiV Healthcare Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<br></span><span class="Bold">Â </span> </p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, POSTTREATMENT EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B IN CO-INFECTED PATIENTS, DIFFERENT FORMULATIONS OF LAMIVUDINE.</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Patients with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use with Other Lamivudine- and Emtricitabine-containing Products</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use with Interferon- and Ribavirin-based Regimens</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Subjects</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience in Pediatric Subjects</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Interferon- and Ribavirin-based Regimens</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Zalcitabine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Trimethoprim/Sulfamethoxazole (TMP/SMX)</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs with No Observed Interactions with Lamivudine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Subjects</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Subjects</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, POSTTREATMENT EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B IN CO-INFECTED PATIENTS, DIFFERENT FORMULATIONS OF LAMIVUDINE.</h1>
<br><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span><br><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>].</span></span><br><br><span class="Bold">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B<br><br>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue lamivudine and areÂ co-infected with HIV-1 and HBV. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span><br>Â <br></span><span class="Bold">Important Differences among Lamivudine-containing Products<br><br>Lamivudine tablets (used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) contain a higher dose of the active ingredient (lamivudine) than EPIVIR-HBV<span class="Sup">Â®</span> tablets and oral solution (used to treat chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>). Patients with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should receive only dosage forms appropriate for treatment of HIV-1 <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<br><p class="First">Lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Limitation of use: The dosage of this product is for HIV-1 and not for HBV.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<ul class="Disc">
<li>The recommended oral dose of lamivudine tablets in HIV-1-infected adults is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily, in combination with other antiretroviral agents. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.<span class="Italics"></span>
</li>
<li>Lamivudine tablets may be taken with or without food.<span class="Italics"></span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First" style="border-left:1px solid;">Lamivudine tablets are available as scored tablets for HIV-1-infected pediatric patients who weigh at least 14 kg and for whom a solid dosage form is appropriate. Before prescribing lamivudine tablets, children should be assessed for the ability to swallow tablets. If a child is unable to <span class="XmChange">reliably </span>swallow lamivudine tablets, the oral solution formulation should be prescribed. The recommended oral dosage of lamivudine tablets for HIV-1-infected pediatric patients is presented in Table 1.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 1. Dosing Recommendations for Lamivudine Scored (150 mg) Tablets in Pediatric Patients  
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">
<span class="Bold">Weight</span><br><span class="Bold">(kg)</span><br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Twice-daily Dosing Regimen Using Scored 150 mg Tablet</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">AM Dose</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">PM Dose</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Total Daily Dose</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">14 to &lt;20<br>
</td>
<td class="Rrule" align="center" valign="top">Â½Â  tablet (75 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">Â½ tablet (75 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">150 mg<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">â‰¥20 to &lt;25<br>
</td>
<td class="Rrule" align="center" valign="top">Â½Â  tablet (75 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">1 tablet (150 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">225 mg<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">â‰¥25<br>
</td>
<td class="Rrule" align="center" valign="top">1 tablet (150 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">1 tablet (150 mg)<br>
</td>
<td class="Rrule" align="center" valign="top">300 mg<br>
</td>
</tr>
</tbody>
</table>
<br><p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Companyâ€™s EPIVIR<span class="Sup">Â®</span> (lamivudine) tablets. However, due to ViiV Healthcare Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<br><p class="First">Dosing of lamivudine tablets is adjusted in accordance with renal function. Dosage adjustments are listed in Table 2 <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 2. Adjustment of Dosage of Lamivudine Tablets in Adults and Adolescents (Greater than or Equal toÂ 25 kg) in Accordance with Creatinine Clearance 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<br>Creatinine Clearance (mL/min)<br>
</td>
<td class="Rrule" align="center" valign="top">Recommended Dosage of Lamivudine Tablets <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â â‰¥50<br>
</td>
<td class="Rrule" valign="top">Â Â Â 150 mg twice daily or 300 mg once daily<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â 30 to 49<br>
</td>
<td class="Rrule" valign="top">Â Â Â 150 mg once daily<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â 15 to 29<br>
</td>
<td class="Rrule" valign="top">Â Â Â 150 mg first dose, then 100 mg once daily<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â 5 to 14<br>
</td>
<td class="Rrule" valign="top">Â Â Â 150 mg first dose, then 50 mg once daily<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â &lt;5<br>
</td>
<td class="Rrule" valign="top">Â Â Â 50 mg first dose, then 25 mg once daily<br>
</td>
</tr>
</tbody>
</table>
<br><p>No additional dosing of lamivudine tablets is required after routine (4-hour) hemodialysis or peritoneal dialysis.<br><br>Although there are insufficient data to recommend a specific dose adjustment of lamivudine tablets in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a reduction in the dose and/or an increase in the dosing interval should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<br><br><ul class="Disc"><li>
<span class="Bold">Lamivudine Scored </span><span class="Bold">Tablets</span>
</li></ul>
<br><p class="First">150 mg, are white to off-white, film-coated, oval shaped tablets, debossed with â€˜66â€™ and â€˜Yâ€™ on either side of the score line on one side and plain with a score line on the other side.</p>
<br><ul class="Disc"><li><span class="Bold">Lamivudine Tablets</span></li></ul>
<p>300 mg, are white to off-white, film-coated, oval shaped tablets, debossed with â€˜67 Yâ€™ on one side and plain on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First">Lamivudine tablets are contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any of the components of the product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering lamivudine to any patient with known risk factors for liver disease; however, cases also have been reported in patients with no known risk factors. Treatment with lamivudine should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Patients with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<br><p class="First"><span class="Underline">Posttreatment Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span><br><br></span>In clinical trials in non-HIV-1-infected patients treated with lamivudine for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of HBV DNA. Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from postmarketing experience after changes from lamivudine-containing HIV-1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. There is insufficient evidence to determine whether re-initiation of lamivudine alters the course of posttreatment exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.<br><br><span class="Underline">Important Differences among Lamivudine-containing Products</span><br><br>Lamivudine tablets contain a higher dose of the same active ingredient (lamivudine) than EPIVIR-HBV tablets and EPIVIR-HBV oral solution. EPIVIR-HBV was developed for patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. The formulation and dosage of lamivudine in EPIVIR-HBV are not appropriate for patients co-infected with HIV-1 and HBV. Safety and efficacy of lamivudine have not been established for treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in patients co-infected with HIV-1 and HBV. If treatment with EPIVIR-HBV is prescribed for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B for a patient with unrecognized or untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, rapid emergence of HIV-1 resistance is likely to result because of the subtherapeutic dose and the inappropriateness of monotherapy HIV-1 treatment. If a decision is made to administer lamivudine to patients co-infected with HIV-1 and HBV, lamivudine tablets, lamivudine oral solution or another product containing the higher dose of lamivudine should be used as part of an appropriate combination regimen.<br><br><span class="Underline">Emergence of Lamivudine-resistant HBV<br></span><br>In non-HIV-1-infected patients treated with lamivudine for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response (see full prescribing information for EPIVIR-HBV for additional information). Emergence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected patients who have received lamivudine-cotaining antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use with Other Lamivudine- and Emtricitabine-containing Products</h2>
<p class="First">Lamivudine is one of multiple lamivudine-containing products. Concomitant administration of lamivudine with other products containing lamivudine is not recommended. Concomitant use of lamivudine with emtricitabine-containing products is also not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use with Interferon- and Ribavirin-based Regimens</h2>
<br><p class="First"><span class="Italics">In vitro </span>studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine. Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>], </span>hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and lamivudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of lamivudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6). See the complete prescribing information for interferon and ribavirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<br><p class="First">In pediatric patients with a history of prior antiretroviral nucleoside exposure, a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, or other significant risk factors for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, lamivudine should be used with caution. Treatment with lamivudine should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur <span class="Italics">[see <span class="Italics"><a href="#Section_6.1">Adverse Reactions  (6.1)</a></span></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including lamivudine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.<br><br><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Fat Redistribution</h2>
<br><p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>, <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>, <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Subjects</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br><br>The safety profile of lamivudine in adults is primarily based on 3,568 HIV-1-infected subjects in 7 clinical trials.<br><br>The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, nasal signs and symptoms, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.<br><br>Selected clinical adverse reactions in greater than or equal to 5% of subjects during therapy with lamivudine 150 mg twice daily plus RETROVIR<span class="Sup">Â®</span> 200 mg 3 times daily for up to 24 weeks are listed in Table 3.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 3. Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in Four Controlled Clinical Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002)  
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span> Either zidovudine monotherapy or zidovudine in combination with zalcitabine. </td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Adverse Reaction</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Lamivudine 150 mg</span><br><span class="Bold">Twice Daily</span><br><span class="Bold">plus RETROVIR</span><br><span class="Bold">(n = 251)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">RETROVIR<span class="Sup">a</span></span><br><span class="Bold">(n = 230)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Body as a Whole</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" valign="top">35%<br>
</td>
<td class="Rrule" align="center" valign="top">27%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> &amp; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">27%<br>
</td>
<td class="Rrule" align="center" valign="top">23%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span><br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Digestive</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">33%<br>
</td>
<td class="Rrule" align="center" valign="top">29%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">18%<br>
</td>
<td class="Rrule" align="center" valign="top">22%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">13%<br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span><br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span><br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Nervous System</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span><br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> &amp; other <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Respiratory</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â Nasal signs &amp; symptoms<br>
</td>
<td class="Rrule" align="center" valign="top">20%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span><br>
</td>
<td class="Rrule" align="center" valign="top">18%<br>
</td>
<td class="Rrule" align="center" valign="top">13%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Skin</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Musculoskeletal</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>:</span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 9 out of 2,613 adult subjects (0.3%) who received lamivudine in controlled clinical trials EPV20001, NUCA3001, NUCB3001, NUCA3002, NUCB3002, and NUCB3007 <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>].</span></p>
<p><span class="Italics"><br>Lamivudine 300 mg Once Daily:</span>The types and frequencies of clinical adverse reactions reported in subjects receiving lamivudine 300 mg once daily or lamivudine 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) for 48 weeks were similar.<br><br>Selected laboratory abnormalities observed during therapy are summarized in Table 4.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 4. Frequencies of Selected Grade 3 to 4 Laboratory Abnormalities in Adults in Four 24-Week Surrogate Endpoint Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002) and a Clinical Endpoint Trial (NUCB3007)  
			</span></caption>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">a</span> The median duration on study was 12 months.<br><span class="Sup">b</span> Either zidovudine monotherapy or zidovudine in combination with zalcitabine.<br><span class="Sup">c</span> Current therapy was either zidovudine, zidovudine plus didanosine, or zidovudine plus zalcitabine.<br>        ULN = Upper limit of normal.<br>        ND = Not done.</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">
<span class="Bold">Test</span><br><span class="Bold">(Threshold Level)</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">24-Week Surrogate Endpoint</span><br><span class="Bold">Trials</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Clinical Endpoint</span><br><span class="Bold">Trial</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Lamivudine plus</span><br><span class="Bold">RETROVIR</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">RETROVIR<span class="Sup">b</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Lamivudine plus</span><br><span class="Bold">Current</span><br><span class="Bold">Therapy</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo plus</span><br><span class="Bold">Current</span><br><span class="Bold">Therapy<span class="Sup">c</span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Absolute neutrophil count<br>(&lt;750/mm<span class="Sup">3</span>)<br>
</td>
<td class="Rrule" align="center" valign="top">7.2%<br>
</td>
<td class="Rrule" align="center" valign="top">5.4%<br>
</td>
<td class="Rrule" align="center" valign="top">15%<br>
</td>
<td class="Rrule" align="center" valign="top">13%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Hemoglobin (&lt;8 g/dL)<br>
</td>
<td class="Rrule" align="center" valign="top">2.9%<br>
</td>
<td class="Rrule" align="center" valign="top">1.8%<br>
</td>
<td class="Rrule" align="center" valign="top">2.2%<br>
</td>
<td class="Rrule" align="center" valign="top">3.4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Platelets (&lt;50,000/mm<span class="Sup">3</span>)<br>
</td>
<td class="Rrule" align="center" valign="top">0.4%<br>
</td>
<td class="Rrule" align="center" valign="top">1.3%<br>
</td>
<td class="Rrule" align="center" valign="top">2.8%<br>
</td>
<td class="Rrule" align="center" valign="top">3.8%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">ALT (&gt;5 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">3.7%<br>
</td>
<td class="Rrule" align="center" valign="top">3.6%<br>
</td>
<td class="Rrule" align="center" valign="top">3.8%<br>
</td>
<td class="Rrule" align="center" valign="top">1.9%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">AST (&gt;5 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">1.7%<br>
</td>
<td class="Rrule" align="center" valign="top">1.8%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
<td class="Rrule" align="center" valign="top">2.1%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Bilirubin (&gt;2.5 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">0.8%<br>
</td>
<td class="Rrule" align="center" valign="top">0.4%<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
<td class="Rrule" align="center" valign="top">ND<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Amylase (&gt;2 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">4.2%<br>
</td>
<td class="Rrule" align="center" valign="top">1.5%<br>
</td>
<td class="Rrule" align="center" valign="top">2.2%<br>
</td>
<td class="Rrule" align="center" valign="top">1.1%<br>
</td>
</tr>
</tbody>
</table>
<p>The frequencies of selected laboratory abnormalities reported in subjects receiving lamivudine 300 mg once daily or lamivudine 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) were similar.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience in Pediatric Subjects</h2>
<p class="First">Lamivudine oral solution has been studied in 638 pediatric subjects aged 3 months to 18 years in 3 clinical trials.<br><br>Selected clinical adverse reactions and physical findings with a greater than or equal to 5% frequency during therapy with lamivudine 4 mg per kg twice daily plus RETROVIR 160 mg per m<span class="Sup">2</span> 3 times daily in therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 5.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 5.Â  Selected Clinical Adverse Reactions and Physical Findings (Greater than or Equal to 5% Frequency) in Pediatric Subjects in Trial ACTG300  
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span>Â  Includes <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, discharge, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of an ear. </td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Adverse Reaction</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Lamivudine plus</span><br><span class="Bold">RETROVIR</span><br><span class="Bold">(n = 236)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Didanosine</span><br><span class="Bold">(n = 235)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Body as a Whole</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>
</td>
<td class="Rrule" align="center" valign="top">25%<br>
</td>
<td class="Rrule" align="center" valign="top">32%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Digestive</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span><br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">Splenomegaly</span><br>
</td>
<td class="Rrule" align="center" valign="top">5%<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Respiratory</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span><br>
</td>
<td class="Rrule" align="center" valign="top">15%<br>
</td>
<td class="Rrule" align="center" valign="top">18%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span><br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Ear, Nose, and Throat</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â Signs or symptoms of ears<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">7%Â  <br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Nasal discharge</span> or congestion<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Other</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span><br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
<td class="Rrule" align="center" valign="top">14%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span><br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span><br><br><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, which has been fatal in some cases, has been observed in antiretroviral nucleoside-experienced pediatric subjects receiving lamivudine alone or in combination with other antiretroviral agents. In an open-label dose-escalation trial (NUCA2002), 14 subjects (14%) developed <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while receiving monotherapy with lamivudine. Three of these subjects died of complications of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. In a second open-label trial (NUCA2005), 12 subjects (18%) developed <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. In Trial ACTG300, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> was not observed in 236 subjects randomized to lamivudine plus RETROVIR. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 1 subject in this trial who received open-label lamivudine in combination with RETROVIR and ritonavir following discontinuation of didanosine monotherapy <span class="Italics">[see </span><span class="Italics"><a href="#Section_5.5">Warnings and Precautions (5.5)</a></span><span class="Italics">].<br></span><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> and </span><span class="Underline">Peripheral Neuropathies</span><br><br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> and peripheral neuropathies were reported in 15 subjects (15%) in Trial NUCA2002, 6 subjects (9%) in Trial NUCA2005, and 2 subjects (less than 1%) in Trial ACTG300.<br><br>Selected laboratory abnormalities experienced by therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 6.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 6. Frequencies of Selected Grade 3 to 4 Laboratory Abnormalities in Pediatric Subjects in Trial ACTG300 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">ULN = Upper limit of normal.</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Test</span><br><span class="Bold">(Threshold Level)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Lamivudine plus</span><br><span class="Bold">RETROVIR</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Didanosine</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Absolute neutrophil count (&lt;400/mm<span class="Sup">3</span>)<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Hemoglobin (&lt;7 g/dL)<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Platelets (&lt;50,000/mm<span class="Sup">3</span>)<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">ALT (&gt;10 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">1%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">AST (&gt;10 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">2%<br>
</td>
<td class="Rrule" align="center" valign="top">4%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Lipase (&gt;2.5 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Total Amylase (&gt;2.5 x ULN)<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
<td class="Rrule" align="center" valign="top">3%<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Companyâ€™s EPIVIR<span class="Sup">Â®</span> (lamivudine) tablets. However, due to ViiV Healthcare Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<br><p><span class="Underline">Neonates<br></span><br>Limited short-term safety information is available from 2 small, uncontrolled trials in South Africa in neonates receiving lamivudine with or without zidovudine for the first week of life following maternal treatment starting at Week 38 or 36 of gestation <span class="Italics">[see <span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>]</span>. Selected adverse reactions reported in these neonates included increased liver function tests, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; 3 neonates died (1 from <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> with <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, 1 from <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">traumatic injury</span>, and 1 from unknown causes). Two other nonfatal <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> cases were reported, including 1 with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>; 1 infant had transient <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. The absence of control groups limits assessments of causality, but it should be assumed that perinatally exposed infants may be at risk for adverse reactions comparable to those reported in pediatric and adult HIV-1-infected patients treated with lamivudine-containing combination regimens. Long-term effects of <span class="Italics">in utero</span> and infant lamivudine exposure are not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of lamivudine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine.<br><span class="Underline"><br>Body as a Whole<br></span><br>Redistribution/accumulation of body fat <span class="Italics">[see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>]</span>.<br><span class="Underline"><br>Endocrine and Metabolic<br></span><br><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>.<br><span class="Underline"><br>General<br></span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.<br><span class="Underline"><br>Hemic and Lymphatic<br></span><br><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy).<br><span class="Underline"><br>Hepatic and Pancreatic<br></span><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, posttreatment exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>, <a href="#Section_5.1">Warnings and Precautions (5.1</a>, <a href="#Section_5.2">5.2)</a>]</span>.<br><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><br></span><br><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.<br><span class="Underline"><br>Musculoskeletal<br></span><br><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, CPK elevation, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.<br><span class="Underline"><br>Skin<br></span><br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<br><p class="First">Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim). No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Interferon- and Ribavirin-based Regimens</h2>
<br><p class="First">Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>, </span><span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Zalcitabine</h2>
<br><p class="First">Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Therefore, use of lamivudine in combination with zalcitabine is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Trimethoprim/Sulfamethoxazole (TMP/SMX)</h2>
<br><p class="First">No change in dose of either drug is recommended. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs with No Observed Interactions with Lamivudine</h2>
<br><p class="First">A drug interaction trial showed no clinically significant interaction between lamivudine and zidovudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Pregnancy Exposure Registry<br></span><br>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. Physicians are encouraged to register patients by calling the Antiretroviral Pregnancy Registry at 1-800-258-4263.<br><span class="Underline"><br>Risk Summary<br></span><br>Available data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> for lamivudine compared with the background rate for major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). Lamivudine produced embryonic toxicity in rabbits at a dose that produced similar human exposures as the recommended clinical dose. The relevance of animal findings to human pregnancy registry data is not known.<br><span class="Underline"><br>Data<br></span><span class="Italics"><br>Human Data:</span> Based on prospective reports from the Antiretroviral Pregnancy Registry of over 11,000 exposures to lamivudine during pregnancy resulting in live births (including over 4,300 exposed in the first trimester), there was no difference between lamivudine and overall <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of defects in the first trimester was 3.1% (95% CI: 2.6% to 3.7%).<br><br>Lamivudine pharmacokinetics were studied in pregnant women during 2 clinical trials conducted in South Africa. The trials assessed pharmacokinetics in 16 women at 36 weeks gestation using 150 mg lamivudine twice daily with zidovudine, 10 women at 38 weeks gestation using 150 mg lamivudine twice daily with zidovudine, and 10 women at 38 weeks gestation using lamivudine 300 mg twice daily without other antiretrovirals. These trials were not designed or powered to provide efficacy information. Lamivudine pharmacokinetics in pregnant women were similar to those seen in non-pregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples. In a subset of subjects, amniotic fluid specimens were collected following natural rupture of membranes and confirmed that lamivudine crosses the placenta in humans. Amniotic fluid concentrations of lamivudine were typically 2 times greater than maternal serum levels and ranged from 1.2 to 2.5 mcg per mL (150 mg twice daily) and 2.1 to 5.2 mcg per mL (300 mg twice daily).<br><span class="Italics"><br>Animal Data:</span> Studies in pregnant rats showed that lamivudine is transferred to the fetus through the placenta. Reproduction studies with orally administered lamivudine have been performed in rats and rabbits at doses producing plasma levels up to approximately 35 times that for the recommended adult HIV dose. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine was observed. Evidence of embryo-lethality was seen in the rabbit at exposure levels similar to those observed in humans but there was no indication of this effect in the rat at exposure levels up to 35 times those in humans.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation</h2>
<p class="First"><span class="Underline">Risk Summary<br></span><br>The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Because of the potential for HIV-1 transmission mothers should be instructed not to breastfeed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<br><p class="First">The safety and effectiveness of lamivudine in combination with other antiretroviral agents have been established in pediatric patients aged 3 months and older <span class="Italics">[see <a href="#Section_2.2">Dosage and Administration (2.2)</a>, <a href="#Section_6.3">Adverse Reactions (6.2)</a>, <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>, <a href="#Section_14.3">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br><p class="First">Clinical trials of lamivudine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, because lamivudine is substantially excreted by the kidney and elderly patients are more likely to have decreased renal function, renal function should be monitored and dosage adjustments should be made accordingly <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a>, <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<br><p class="First">Reduction of the dosage of lamivudine is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a>, <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<br><p class="First">There is no known antidote for lamivudine. One case of an adult ingesting 6 g of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Two cases of pediatric <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> were reported in Trial ACTG300. One case involved a single dose of 7 mg per kg of lamivudine; the second case involved use of 5 mg per kg of lamivudine twice daily for 30 days. There were no clinical signs or symptoms noted in either case. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> event. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored, and standard supportive treatment applied as required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">Lamivudine(also known as 3TC) is a synthetic nucleoside analogue with activity against HIV-1 and HBV. The chemical name of lamivudine is (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2',3'-dideoxy, 3'-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3. It has the following structural formula:</p>
<br><div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-str.jpg"></div>
<br><p>Lamivudine is a white to off-white solid with a solubility of approximately 70 mg per mL in water at 20Â°C.<br><br>Lamivudine tablets are for oral administration. Each scored 150 mg film-coated tablet and 300 mg film-coated tablet contains 150 mg and 300 mg of lamivudine and the following inactive ingredients hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Lamivudine is an antiviral agent <span class="Italics">[see <a href="#Section_12.4">Microbiology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First"><span class="Underline">Pharmacokinetics in Adults<br></span><br>The pharmacokinetic properties of lamivudine have been studied in asymptomatic, HIV-1-infected adult subjects after administration of single intravenous (IV) doses ranging from 0.25 to 8 mg per kg, as well as single and multiple (twice-daily regimen) oral doses ranging from 0.25 to 10 mg per kg.<br><br>The pharmacokinetic properties of lamivudine have also been studied as single and multiple oral doses ranging from 5 mg to 600 mg per day administered to HBV-infected subjects.<br><br>The steady-state pharmacokinetic properties of the lamivudine 300 mg tablet once daily for 7 days compared with the lamivudine 150 mg tablet twice daily for 7 days were assessed in a crossover trial in 60 healthy subjects. Lamivudine 300 mg once daily resulted in lamivudine exposures that were similar to lamivudine 150 mg twice daily with respect to plasma AUC<span class="Sub">24,ss</span>; however, C<span class="Sub">max,ss </span>was 66% higher and the trough value was 53% lower compared with the 150 mg twice-daily regimen. Intracellular lamivudine triphosphate exposures in peripheral blood mononuclear cells were also similar with respect to AUC<span class="Sub">24,ss</span> and C<span class="Sub">max24,ss</span>; however, trough values were lower compared with the 150 mg twice-daily regimen. Inter-subject variability was greater for intracellular lamivudine triphosphate concentrations versus lamivudine plasma trough concentrations.<br><span class="Italics"><br>Absorption and Bioavailability: </span>Lamivudine was rapidly absorbed after oral administration in HIV-1-infected subjects. Absolute bioavailability in 12 adult subjects was 86% Â± 16% (mean Â± SD) for the 150 mg tablet and 87% Â± 13% for the oral solution. After oral administration of 2 mg per kg twice a day to 9 adults with HIV-1, the peak serum lamivudine concentration (C<span class="Sub">max</span>) was 1.5 Â± 0.5 mcg per mL (mean Â± SD). The area under the plasma concentration versus time curve (AUC) and C<span class="Sub">max</span> increased in proportion to oral dose over the range from 0.25 to 10 mg per kg. <br><br>The accumulation ratio of lamivudine in HIV-1-positive asymptomatic adults with normal renal function was 1.5 following 15 days of oral administration of 2 mg per kg twice daily.<span class="Italics"><br><br>Effects of Food on Oral Absorption: </span>An investigational 25 mg dosage form of lamivudine was administered orally to 12 asymptomatic, HIV-1-infected subjects on 2 occasions, once in the fasted state and once with food (1,099 kcal; 75 grams fat, 34 grams protein, 72 grams carbohydrate). Absorption of lamivudine was slower in the fed state (T<span class="Sub">max</span>: 3.2 Â± 1.3 hours) compared with the fasted state (T<span class="Sub">max</span>: 0.9 Â± 0.3 hours); C<span class="Sub">max</span> in the fed state was 40% Â± 23% (mean Â± SD) lower than in the fasted state. There was no significant difference in systemic exposure (AUC<span class="Sub">âˆž</span>) in the fed and fasted states; therefore, lamivudine tablets may be administered with or without food.<span class="Italics"><br><br>Distribution: </span>The apparent volume of distribution after IV administration of lamivudine to 20 subjects was 1.3 Â± 0.4 L per kg, suggesting that lamivudine distributes into extravascular spaces. Volume of distribution was independent of dose and did not correlate with body weight.<br><br>Binding of lamivudine to human plasma proteins is low (less than 36%). <span class="Italics">In vitro</span> studies showed that over the concentration range of 0.1 to 100 mcg per mL, the amount of lamivudine associated with erythrocytes ranged from 53% to 57% and was independent of concentration.</p>
<span class="Italics"></span><br><br><p><span class="Italics">Metabolism:</span> Metabolism of lamivudine is a minor route of elimination. In man, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. Within 12 hours after a single oral dose of lamivudine in 6 HIV-1-infected adults, 5.2% Â± 1.4% (mean Â± SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Serum concentrations of this metabolite have not been determined.</p>
<span class="Italics"></span><br><br><p><span class="Italics">Elimination:</span>The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. In 9 healthy subjects given a single 300 mg oral dose of lamivudine, renal clearance was 199.7 Â± 56.9 mL per min (mean Â± SD). In 20 HIV-1-infected subjects given a single IV dose, renal clearance was 280.4 Â± 75.2 mL per min (mean Â± SD), representing 71% Â± 16% (mean Â± SD) of total clearance of lamivudine.<br><br>In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t<span class="Sub">Â½</span>) ranged from 5 to 7 hours. In HIV-1-infected subjects, total clearance was 398.5 Â± 69.1 mL per min (mean Â± SD). Oral clearance and elimination half-life were independent of dose and body weight over an oral dosing range of 0.25 to 10 mg per kg.<br><br><span class="Underline">Special Populations<br><br></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span></p>
<span class="Italics"></span><p>The pharmacokinetic properties of lamivudine have been determined in a small group of HIV-1-infected adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (Table 7).</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 7. Pharmacokinetic Parameters (Mean Â± SD) after a Single 300 mg Oral Dose of Lamivudine in 3 Groups of Adults with Varying Degrees of Renal Function 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">Â <br>Parameter<br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">Creatinine Clearance Criterion<br>            (Number of Subjects)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&gt;60 mL/min <br>            (n = 6)<br>
</td>
<td class="Rrule" align="center" valign="top">10 to 30 mL/min <br>(n = 4)<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;10 mL/min <br>            (n = 6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Creatinine clearance (mL/min)<br>
</td>
<td class="Rrule" align="center" valign="top">111 Â± 14<br>
</td>
<td class="Rrule" align="center" valign="top">28 Â± 8<br>
</td>
<td class="Rrule" align="center" valign="top">6 Â± 2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â C<span class="Sub">max</span> (mcg/mL)<br>
</td>
<td class="Rrule" align="center" valign="top">2.6 Â± 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">3.6 Â± 0.8<br>
</td>
<td class="Rrule" align="center" valign="top">5.8 Â± 1.2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â AUC<span class="Sub">âˆž</span> (mcgâ€¢hr/mL)<br>
</td>
<td class="Rrule" align="center" valign="top">11 + 1.7<br>
</td>
<td class="Rrule" align="center" valign="top">48 Â± 19<br>
</td>
<td class="Rrule" align="center" valign="top">157 Â± 74<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â C1/F (mL/min)<br>
</td>
<td class="Rrule" align="center" valign="top">464 Â± 76<br>
</td>
<td class="Rrule" align="center" valign="top">114 Â± 34<br>
</td>
<td class="Rrule" align="center" valign="top">36 Â± 11<br>
</td>
</tr>
</tbody>
</table>
<p>Exposure (AUC<span class="Sub">âˆž</span>), C<span class="Sub">max</span>, and half-life increased with diminishing renal function (as expressed by creatinine clearance). Apparent total oral clearance (Cl/F) of lamivudine decreased as creatinine clearance decreased. T<span class="Sub">max</span> was not significantly affected by renal function. Based on these observations, it is recommended that the dosage of lamivudine be modified in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#Section_2.3">Dosage and Administration (2.3)</a>]</span>.<br><br>Based on a trial in otherwise healthy subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, hemodialysis increased lamivudine clearance from a mean of 64 to 88 mL per min; however, the length of time of hemodialysis (4 hours) was insufficient to significantly alter mean lamivudine exposure after a single-dose administration. Continuous ambulatory peritoneal dialysis and automated peritoneal dialysis have negligible effects on lamivudine clearance. Therefore, it is recommended, following correction of dose for creatinine clearance, that no additional dose modification be made after routine hemodialysis or peritoneal dialysis. <br><br>It is not known whether lamivudine can be removed by continuous (24-hour) hemodialysis. <br><br>The effects of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on lamivudine pharmacokinetics in pediatric patients are not known.<span class="Italics"><br><br><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>The pharmacokinetic properties of lamivudine have been determined in adults with impaired hepatic function. Pharmacokinetic parameters were not altered by diminishing hepatic function; therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function. Safety and efficacy of lamivudine have not been established in the presence of decompensated liver disease.<br><br><span class="Italics">Pediatric Patients: </span>The pharmacokinetics of lamivudine have been studied after either single or repeat doses ofÂ lamivudine tabletsÂ in pediatric subjects. Pediatric subjects receiving lamivudine oral solution according to the recommended dosage regimen achieved approximately 25% lower plasma concentrations of lamivudine compared with HIV-1-infected adults. Pediatric subjects receiving lamivudine oral tablets achieved plasma concentrations comparable to or slightly higher than those observed in adults. The absolute bioavailability of both lamivudine tablets and oral solution are lower in children than adults. The relative bioavailability of lamivudine oral solution is approximately 40% lower than tablets containing lamivudine in pediatric subjects despite no difference in adults.Â  The mechanisms for the diminished absolute bioavailability of lamivudine and relative bioavailability of lamivudine solution are unknown.<br><br>Distribution of lamivudine into cerebrospinal fluid (CSF) was assessed in 38 pediatric subjects after multiple oral dosing with lamivudine. CSF samples were collected between 2 and 4 hours postdose. At the dose of 8 mg per kg per day, CSF lamivudine concentrations in 8Â subjects ranged from 5.6% to 30.9% (mean Â± SD of 14.2% Â± 7.9%) of the concentration in a simultaneous serum sample, with CSF lamivudine concentrations ranging from 0.04 to 0.3 mcg per mL.<br><br>Limited, uncontrolled pharmacokinetic and safety data are available from administration of lamivudine (and zidovudine) to 36 infants aged up to 1 week in 2 trials in South Africa. In these trials, lamivudine clearance was substantially reduced in 1-week-old neonates relative to pediatric subjects (aged over 3 months) studied previously. There is insufficient information to establish the time course of changes in clearance between the immediate neonatal period and the age-ranges over 3 months old <span class="Italics">[see </span><span class="Italics"><a href="#Section_6.3">Adverse Reactions (6.2)</a></span><span class="Italics">].<br></span><span class="Bold"><br>Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Companyâ€™s EPIVIR<span class="Sup">Â®</span> (lamivudine) tablets. However, due to ViiV Healthcare Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<br></span><span class="Italics"><br>Geriatric Patients: </span>The pharmacokinetics of lamivudine after administration of lamivudine to subjects over 65 years have not been studied <span class="Italics">[see <span class="Italics"><a href="#Section_8.5">Use in Specific Populations (8.5)</a></span>]</span>.<span class="Italics"><br><br>Gender: </span>There are no significant gender differences in lamivudine pharmacokinetics.<span class="Italics"><br><br>Race: </span>There are no significant racial differences in lamivudine pharmacokinetics.<br><br><span class="Underline">Drug Interactions<br><br></span><span class="Italics">Interferon Alfa: </span>There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between lamivudine and interferon alfa in a trial of 19 healthy male subjects <span class="Italics">[see <span class="Italics"><a href="#Section_5.4">Warnings and Precautions (5.4)</a></span>]</span>.</p>
<span class="Italics"></span><br><br><p>Ribavirin: <span class="Italics">In vitro</span> data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected subjects <span class="Italics">[see <span class="Italics"><a href="#Section_5.4">Warnings and Precautions (5.4)</a></span>]</span>.</p>
<span class="Italics"></span><br><br><p>Trimethoprim/Sulfamethoxazole: Lamivudine and TMP/SMX were coadministered to 14 HIV-1-positive subjects in a single-center, open-label, randomized, crossover trial. Each subject received treatment with a single 300 mg dose of lamivudine and TMP 160 mg/SMX 800 mg once a day for 5 days with concomitant administration of lamivudine 300 mg with the fifth dose in a crossover design. Coadministration of TMP/SMX with lamivudine resulted in an increase of 43% Â± 23% (mean Â± SD) in lamivudine AUC<span class="Sub">âˆž</span>, a decrease of 29% Â± 13% in lamivudine oral clearance, and a decrease of 30% Â± 36% in lamivudine renal clearance. The pharmacokinetic properties of TMP and SMX were not altered by coadministration with lamivudine <span class="Italics">[see <span class="Italics"><a href="#Section_7.3">Drug Interactions (7.3)</a></span>]</span>. <br><br><span class="Italics">Zidovudine: </span>No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIV-1-infected adult subjects given a single dose of zidovudine (200 mg) in combination with multiple doses of lamivudine (300 mg every 12 h) <span class="Italics">[see <span class="Italics"><a href="#Section_7.4">Drug Interactions (7.4)</a></span>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<br><p class="First"><span class="Underline">Mechanism of Action<br></span><br>Intracellularly, lamivudine is phosphorylated to its active 5'-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is the inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue into viral DNA. 3TC-TP is a weak inhibitor of mammalian DNA polymerases Î±, Î², and Î³.<br><br><span class="Underline">Antiviral Activity<br></span><br>The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) using standard susceptibility assays. EC<span class="Sub">50</span> values (50% effective concentrations) were in the range of 0.003 to 15 ÂµM (1 ÂµM = 0.23 mcg per mL). HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.429 ÂµM (range: 0.2 to 2.007 ÂµM) from Virco (n = 92 baseline samples from COLA40263) and 2.35 ÂµM (range: 1.37 to 3.68 ÂµM) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC<span class="Sub">50 </span>values of lamivudine against different HIV-1 clades (A-G) ranged from 0.001 to 0.12 ÂµM, and against HIV-2 isolates from 0.003 to 0.12 ÂµM in peripheral blood mononuclear cells. Ribavirin (50 ÂµM) decreased the anti-HIV-1 activity of lamivudine by 3.5 fold in MT-4 cells. In HIV-1-infected MT-4 cells, lamivudine in combination with zidovudine at various ratios exhibited synergistic antiretroviral activity. Please see the full prescribing information for EPIVIR-HBV for information regarding the inhibitory activity of lamivudine against HBV.<br><br><span class="Underline">Resistance<br></span><br>Lamivudine-resistant variants of HIV-1 have been selected in cell culture. Genotypic analysis showed that the resistance was due to a specific amino acid substitution in the HIV-1 reverse transcriptase at codon 184 changing the methionine to either isoleucine or valine (Ml84V/I).<br><br>HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to both lamivudine and zidovudine have been isolated from subjects. Susceptibility of clinical isolates to lamivudine and zidovudine was monitored in controlled clinical trials. In subjects receiving lamivudine monotherapy or combination therapy <br>with lamivudine plus zidovudine, HIV-1 isolates from most subjects became phenotypically and genotypically resistant to lamivudine within 12 weeks. In some subjects harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of mutations conferring resistance to zidovudine.<br><br>Lamivudine-resistant HBV isolates develop substitutions (rtM204V/I) in the YMDD motif of the catalytic domain of the viral reverse transcriptase. rtM204V/I substitutions are frequently accompanied by other substitutions (rtV173L, rtL180M) which enhance the level of lamivudine resistance or act as compensatory mutations improving replication efficiency. Other substitutions detected in lamivudine-resistant HBV isolates include: rtL80I and rtAl81T. Similar HBV mutants have been reported in HIV-1-infected subjects who received lamivudine-containing antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span><br><br><span class="Underline">Cross-resistance<br></span><br>Lamivudine-resistant HIV-1 mutants were cross-resistant to didanosine (ddI) and zalcitabine (ddC). In some subjects treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple reverse transcriptase inhibitors, including lamivudine, have emerged.<br><br><span class="Underline">Genotypic and Phenotypic Analysis of On-therapy HIV-1 Isolates from Subjects with Virologic Failure<br></span><br><span class="Italics">Trial EPV20001:Â  </span>Fifty-three of 554 (10%) subjects enrolled in EPV20001 were identified as virological failures (plasma HIV-1 RNA level greater than or equal to 400 copies per mL) by Week 48. Twenty-eight subjects were randomized to the lamivudine once-daily treatment group and 25 to the lamivudine twice-daily treatment group. The median baseline plasma HIV-1 RNA levels of subjects in the lamivudine once-daily group and lamivudine twice-daily group were 4.9 log<span class="Sub">10</span> copies per mL and 4.6 log<span class="Sub">10</span> copies per mL, respectively.<br><br><br>Genotypic analysis of on-therapy isolates from 22 subjects identified as virologic failures in the lamivudine once-daily group showed that isolates from 0 of 22 subjects contained treatment-emergent amino acid substitutions associated with zidovudine resistance (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E), isolates from 10 of 22 subjects contained treatment-emergent amino acid substitutions associated with efavirenz resistance (L100I, K101E, K103N, V108I, or Y181C), and isolates from 8 of 22 subjects contained a treatment-emergent lamivudine resistance-associated substitution (M184I or M184V).<br><br>Genotypic analysis of on-therapy isolates from subjects (n = 22) in the lamivudine twice-daily treatment group showed that isolates from 1 of 22 subjects contained treatment-emergent zidovudine resistance substitutions, isolates from 7 of 22 contained treatment-emergent efavirenz resistance substitutions, and isolates from 5 of 22 contained treatment-emergent lamivudine resistance substitutions.<br><br>Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from subjects (n = 13) receiving lamivudine once daily showed that isolates from 12 of 13 subjects were susceptible to zidovudine; isolates from 8 of 13 subjects exhibited a 25- to 295-fold decrease in <br>susceptibility to efavirenz, and isolates from 7 of 13 subjects showed an 85- to 299-fold decrease in susceptibility to lamivudine.<br><br><br>Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from subjects (n = 13) receiving lamivudine twice daily showed that isolates from all 13 subjects were susceptible to zidovudine; isolates from 3 of 13 subjects exhibited a 21- to 342-fold decrease in susceptibility to efavirenz, and isolates from 4 of 13 subjects exhibited a 29- to 159-fold decrease in susceptibility to lamivudine.<br><br><span class="Italics">Trial EPV40001:</span> Fifty subjects received zidovudine 300 mg twice daily plus abacavir 300 mg twice daily plus lamivudine 300 mg once daily and 50 subjects received zidovudine 300 mg plus abacavir 300 mg plus lamivudine 150 mg all twice-daily. The median baseline plasma HIV-1 RNA levels for subjects in the 2 groups were 4.79 log<span class="Sub">10</span> copies per mL and 4.83 log<span class="Sub">10</span> copies per mL, respectively. Fourteen of 50 subjects in the lamivudine once-daily treatment group and 9 of 50 subjects in the lamivudine twice-daily group were identified as virologic failures.<br><br>Genotypic analysis of on-therapy HIV-1 isolates from subjects (n = 9) in the lamivudine once-daily treatment group showed that isolates from 6 subjects had an abacavir and/or lamivudine resistance-associated substitution Ml84V alone. On-therapy isolates from subjects (n = 6) receiving lamivudine twice daily showed that isolates from 2 subjects had Ml84V alone, and isolates from 2 subjects harbored the Ml84V substitution in combination with zidovudine resistance-associated amino acid substitutions.<br><br>Phenotypic analysis of on-therapy isolates from subjects (n = 6) receiving lamivudine once daily showed that HIV-1 isolates from 4 subjects exhibited a 32- to 53-fold decrease in susceptibility to lamivudine. HIV-1 isolates from these 6 subjects were susceptible to zidovudine.<br><br>Phenotypic analysis of on-therapy isolates from subjects (n = 4) receiving lamivudine twice daily showed that HIV-1 isolates from 1 subject exhibited a 45-fold decrease in susceptibility to lamivudine and a 4.5-fold decrease in susceptibility to zidovudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis<br></span><br>Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10 times (mice) and 58 times (rats) those observed in humans at the recommended therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br><span class="Underline"><br>Mutagenesis<br></span><br>Lamivudine was not active in a microbial mutagenicity screen or an <span class="Italics">in vitro</span> cell transformation assay, but showed weak <span class="Italics">in vitro</span> mutagenic activity in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. However, lamivudine showed no evidence of <span class="Italics">in vivo</span> genotoxic activity in the rat at oral doses of up to 2,000 mg per kg, producing plasma levels of 35 to 45 times those in humans at the recommended dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br><span class="Underline"><br>Impairment of Fertility<br></span><br>In a study of reproductive performance, lamivudine administered to rats at doses up to 4,000 mg per kg per day, producing plasma levels 47 to 70 times those in humans, revealed no evidence of impaired fertility and no effect on the survival, growth, and development to weaning of the offspring.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<br><p class="First">The use of lamivudine is based on the results of clinical trials in HIV-1-infected subjects in combination regimens with other antiretroviral agents. Information from trials with clinical endpoints or a combination of CD4+ cell counts and HIV-1 RNA measurements is included below as documentation of the contribution of lamivudine to a combination regimen in controlled trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Subjects</h2>
<br><p class="First">Clinical Endpoint Trial<br><br>NUCB3007 (CAESAR) was a multi-center, double-blind, placebo-controlledÂ trial comparing continued current therapy (zidovudine alone [62% of subjects] or zidovudine with didanosine or zalcitabine [38% of subjects]) to the addition of lamivudine or lamivudine plus an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), randomized 1:2:1. A total of 1,816 HIV-1-infected adults with 25 to 250 CD4+ cells per mm<span class="Sup">3</span> (median = 122 cells per mm<span class="Sup">3</span>) at baseline were enrolled: median age was 36 years, 87% were male, 84% were nucleoside-experienced, and 16% were therapy-naive. The median duration on trial was 12 months. Results are summarized in Table 9.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 9. Number ofÂ Subjects (%) with at Least One HIV-1 Disease Progression Event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">a</span>An investigational non-nucleoside reverse transcriptase inhibitor not approved in the United States. <br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Endpoint<br>
</td>
<td class="Rrule" align="center" valign="top">Current Therapy<br>            (n = 460)<br>
</td>
<td class="Rrule" align="center" valign="top">Lamivudine plus<br>            Current Therapy<br>(n = 896)<br>
</td>
<td class="Rrule" align="center" valign="top">Lamivudine plus an<br>            NNRTI<span class="Sup">a</span> plus<br>            Current Therapy<br>(n = 460)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â HIV-1 progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td class="Rrule" align="center" valign="top">90 (19.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">86 (9.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">41 (8.9%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span><br>
</td>
<td class="Rrule" align="center" valign="top">27 (5.9%)<br>
</td>
<td class="Rrule" align="center" valign="top">23 (2.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">14 (3%)<br>
</td>
</tr>
</tbody>
</table>
<br><p><span class="Underline">Surrogate Endpoint Trials<br></span><span class="Italics"><br>Dual Nucleoside Analogue Trials: </span>Principal clinical trials in the initial development of lamivudine compared lamivudine/zidovudine combinations with zidovudine monotherapy or with zidovudine plus zalcitabine. TheseÂ trials demonstrated the antiviral effect of lamivudine in a 2-drug combination. More recent uses of lamivudine in treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> incorporate it into multiple-drug regimens containing at least 3 antiretroviral drugs for enhanced viral suppression.<br><span class="Italics"><br>Dose Regimen Comparison Surrogate EndpointÂ  TrialsÂ in Therapy-naive Adults:<br><br></span>EPV20001 was a multi-center, double-blind, controlled trial in whichÂ subjects were randomized 1:1 to receive lamivudine 300 mg once daily or lamivudine 150 mg twice daily, in combination with zidovudine 300 mg twice daily and efavirenz 600 mg once daily. A total of 554 antiretroviral treatment-naive HIV-1-infected adults enrolled: male (79%), white (50%), median age of 35 years, baseline CD4+ cell counts of 69 to 1,089 cells per mm<span class="Sup">3 </span>(median = 362 cells per mm<span class="Sup">3</span>), and median baseline plasma HIV-1 RNA of 4.66 log<span class="Sub">10</span> copies per mL. Outcomes of treatment through 48 weeks are summarized in FigureÂ 1 and Table 10.</p>
<br><div class="Figure"><img alt="Figure 2. Virologic Response Through Week 48, EPV2000l*â€  (Intent-to-Treat)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-fig2.jpg"></div>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 10. Outcomes of Randomized Treatment through 48 Weeks (Intent-to-Treat) 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span>Â Achieved confirmed plasma HIV-1 RNA less than 400 copies per mL and maintained through 48 weeks.<br><span class="Sup">bÂ </span>Achieved suppression but rebounded by Week 48, discontinued due to virologic failure, insufficient viral response according to the investigator, or never suppressed through Week 48.<br><span class="Sup">cÂ </span>Includes consent withdrawn, lost to follow-up, protocol violation, data outside the trial-defined schedule, and randomized but never initiated treatment.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Outcome<br>
</td>
<td class="Rrule" align="center" valign="top">Lamivudine 300 mg<br>            Once Daily<br>plus RETROVIR<br>            plus Efavirenz<br>            (n = 278)<br>
</td>
<td class="Rrule" align="center" valign="top">Lamivudine 150 mg<br>            Twice Daily<br>plus RETROVIR<br>            plus Efavirenz<br>            (n = 276)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Responder<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">67%<br>
</td>
<td class="Rrule" align="center" valign="top">65%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Virologic failure<span class="Sup">b</span><br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Discontinued due to clinical progressionÂ Â Â <br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1%<br>
</td>
<td class="Rrule" align="center" valign="top">0%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Discontinued due to adverse eventsÂ Â Â <br>
</td>
<td class="Rrule" align="center" valign="top">6%<br>
</td>
<td class="Rrule" align="center" valign="top">12%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â Discontinued due to other reasons<span class="Sup">cÂ Â Â Â </span><br>
</td>
<td class="Rrule" align="center" valign="top">18%<br>
</td>
<td class="Rrule" align="center" valign="top">14%<br>
</td>
</tr>
</tbody>
</table>
<p>The proportions of subjects with HIV-1 RNA less than 50 copies per mL (via Roche Ultrasensitive assay) through Week 48 were 61% for subjects receiving lamivudine 300 mg once daily and 63% for subjects receiving lamivudine 150 mg twice daily. Median increases in CD4+ cell counts were 144 cells per mm<span class="Sup">3</span> at Week 48 in subjects receiving lamivudine 300 mg once daily and 146 cells per mm<span class="Sup">3</span> for subjects receiving lamivudine 150 mg twice daily.<br><br>A small, randomized, open-label pilot trial, EPV40001, was conducted in Thailand. A total of 159 treatment-naive adult subjects (male 32%, Asian 100%, median age 30 years, baseline median CD4+ cell count 380 cells per mm<span class="Sup">3</span>, median plasma HIV-1 RNA 4.8 log<span class="Sub">10</span> copies per mL) were enrolled. Two of the treatment arms in this trial provided a comparison between lamivudine 300 mg once daily (n = 54) and lamivudine 150 mg twice daily (n = 52), each in combination with zidovudine 300 mg twice daily and abacavir 300 mg twice daily. In intent-to-treat analyses of 48-week data, the proportions of subjects with HIV-1 RNA below 400 copies per mL were 61% (33 of 54) in the group randomized to once-daily lamivudine and 75% (39 of 52) in the group randomized to receive all 3 drugs twice daily; the proportions with HIV-1 RNA below 50 copies per mL were 54% (29 of 54) in the once-daily lamivudine group and 67% (35 of 52) in the all-twice-daily group; and the median increases in CD4+ cell counts were 166 cells per mm<span class="Sup">3</span> in the once-daily lamivudine group and 216 cells per mm<span class="Sup">3</span> in the all-twice-daily group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Subjects</h2>
<p class="First"><span class="Underline">Clinical Endpoint Trial<br></span><br>ACTG300 was a multi-center, randomized, double-blind trial that provided for comparison of lamivudine plus RETROVIR (zidovudine) with didanosine monotherapy. A total of 471 symptomatic, HIV-1-infected therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects were enrolled in these 2 treatment arms. The median age was 2.7 years (range: 6 weeks to 14 years), 58% were female, and 86% were non-white. The mean baseline CD4+ cell count was 868 cells per mm<span class="Sup">3</span> (mean: 1,060 cells per mm<span class="Sup">3</span> and range: 0 to 4,650 cells per mm<span class="Sup">3</span> for subjects aged less than or equal to 5 years; mean: 419 cells per mm<span class="Sup">3</span> and range: 0 to 1,555 cells per mm<span class="Sup">3</span> for subjects aged over 5 years) and the mean baseline plasma HIV-1 RNA was 5 log<span class="Sub">10</span> copies per mL. The median duration on trial was 10.1 months for the subjects receiving lamivudine plus RETROVIR and 9.2 months for subjects receiving didanosine monotherapy. Results are summarized in Table 11.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 11. Number of Subjects (%) Reaching a Primary Clinical Endpoint (Disease Progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>) 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Endpoint</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Lamivudine plus</span><br><span class="Bold">RETROVIR</span><br><span class="Bold">(n = 236)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Didanosine</span><br><span class="Bold">(n = 235)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">HIV-1 disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (total)<br>
</td>
<td class="Rrule" align="center" valign="top">15 (6.4%)<br>
</td>
<td class="Rrule" align="center" valign="top">37 (15.7%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Physical growth failure<br>
</td>
<td class="Rrule" align="center" valign="top">7 (3%)<br>
</td>
<td class="Rrule" align="center" valign="top">6 (2.6%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Central nervous system deterioration<br>
</td>
<td class="Rrule" align="center" valign="top">4 (1.7%)<br>
</td>
<td class="Rrule" align="center" valign="top">12 (5.1%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CDC Clinical Category C<br>
</td>
<td class="Rrule" align="center" valign="top">2 (0.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">8 (3.4%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span><br>
</td>
<td class="Rrule" align="center" valign="top">2 (0.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">11 (4.7%)<br>
</td>
</tr>
</tbody>
</table>
<br><p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Companyâ€™s EPIVIR<span class="Sup">Â®</span> (lamivudine) tablets. However, due to ViiV Healthcare Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<br><p class="First"><span class="Bold">Lamivudine Scored Tablets, 150 mg</span> are white to off-white, film-coated, oval shaped tablets, debossed with â€˜66â€™ and â€˜Yâ€™ on either side of the score line on one side and plain with a score line on the other side.<br><br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Bottle of 60 TabletsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â NDC 65862-552-60<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Carton of 60 (6 x 10) Unit-dose TabletsÂ Â Â Â Â Â Â NDC 65862-552-10<span class="Bold"><br><br>Lamivudine Tablets, 300 mg</span>are white to off-white, film-coated, oval shaped tablets, debossed with â€˜67 Yâ€™ on one side and plain on the other side.<br><br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Bottle of 30 TabletsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â  NDC 65862-553-30<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Carton of 30 (3 x 10) Unit-dose TabletsÂ Â Â Â Â Â Â Â Â NDC 65862-553-10<br><br>Recommended Storage:<br><span class="Bold"><br>Store at </span>20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (<a href="#Section_24">Patient Information</a>).<br><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span><br></span><br>Inform patients that some HIV medicines, including lamivudine, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.<br><span class="Underline"><br>HIV-1/HBV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><br></span><br>Inform patients co-infected with HIV-1 and HBV that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Advise patients to discuss any changes in regimen with their physician <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.<br><span class="Underline"><br>Differences in Formulations of Lamivudine<br></span><br>Advise patients that lamivudine tablets contain a higher dose of the same active ingredient (lamivudine) as EPIVIR-HBV tablets and oral solution. If a decision is made to include lamivudine in the HIV-1 treatment regimen of a patient co-infected with HIV-1 and HBV, the formulation and dosage of lamivudine in lamivudine tablets (not EPIVIR-HBV) should be used <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.<br><span class="Underline"><br>Use with Other Lamivudine-and Emtricitabine-containing Products<br></span><br>Lamivudine should not be coadministered with drugs containing lamivudine or emtricitabine, including COMBIVIR (lamivudine/zidovudine) tablets, EPZICOM (abacavir sulfate and lamivudine) tablets, TRIUMEQ (dolutegravir, abacavair, lamivudine), TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), ATRIPLA (efavirenz, emtricitabine, and tenofovir), EMTRIVA (emtricitabine), STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate), TRUVADA (emtricitabine and tenofovir), or COMPLERA (rilpivirine/emtricitabine/tenofovir) <span class="Italics">[see </span><span class="Italics"><a href="#Section_5.3">Warnings andPrecautions (5.3)</a>]</span>.<br><span class="Underline"><br>HIV-1/HCV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><br></span><br>Inform patients with HIV-1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>.<br><span class="Underline"><br>Risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span><br></span><br>Advise parents or guardians to monitor pediatric patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>.<br><span class="Underline"><br>Redistribution/Accumulation of Body Fat<br></span><br>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including lamivudine, and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>]</span>.<br><span class="Underline"><br>Information about HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br></span><br>Lamivudine is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients must remain on continuous HIV therapy to control HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illness. Patients should be told that sustained decreases in plasma HIV-1 RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should remain under the care of a physician when using lamivudine.<br><br>Patients should be informed to take all HIV medications exactly as prescribed. If you miss a dose of lamivudine tablets, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.<br><br>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<br><ul class="Disc">
<li><span class="Bold">Do not re-use or share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>Continue to practice safer sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>Female patients should be advised not to breastfeed. Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_24"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Lamivudine Tablets<br>(la miv' ue deen)<br></span><span class="Bold"><br>What is the most important information I should know about lamivudine tablets?<br></span><span class="Bold"><br>Lamivudine tablets can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">Build-up of an acid in your blood (<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>). </span><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can happen in some people who take lamivudine tablets or similar medicines (nucleoside analogs). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be hard to identify early because the symptoms could seem like symptoms of other health problems. <span class="Bold">Call your healthcare provider right away if you get any of the following symptoms that could be signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span>
</li></ul>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last">
<td class="Lrule Rrule" valign="top"><ul class="Disc">
<li>feel very weak or tired</li>
<li>unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</li>
<li>feel dizzy or light-headed</li>
<li>have a fast or irregular heartbeat</li>
</ul></td>
<td class="Rrule" valign="top"></td>
</tr></tbody></table>
<br><ul class="Disc"><li>
<span class="Bold">Severe liver problems. </span>Severe liver problems can happen in people who take lamivudine tablets or similar medicines. In some cases these liver problems can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your liver may become large (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and you may develop fat in your liver (steatosis) when you take lamivudine tablets. <span class="Bold">Call your healthcare provider right away if you get any of the following signs of liver problems:</span>
</li></ul>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last">
<td class="Lrule Rrule" valign="top"><ul class="Disc">
<li>your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark or â€œtea-coloredâ€? urine</li>
<li>light-colored stools (bowel movements)</li>
<li>loss of appetite for several days or longer</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on the right side of your stomach area</li>
</ul></td>
<td class="Rrule" valign="top"></td>
</tr></tbody></table>
<br><p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or severe liver problems if you are female, very overweight (obese), or have been taking nucleoside analog medicines for a long time or have risks for liver problems.</span></p>
<ul class="Disc">
<li>
<span class="Bold">Worsening of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </span>If you have HIV-1 (Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, your HBV may get worse (flare-up) if you stop taking lamivudine tablets. A â€œflare-upâ€? is when your HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> suddenly returns in a worse way than before. Worsening liver disease from HBV can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>Do not run out of lamivudine tablets. Refill your prescription or talk to your healthcare provider before your lamivudine tabletsÂ are all gone.</li>
<li>Do not stop lamivudine tablets without first talking to your healthcare provider.<span class="Bold"></span>
</li>
<li>If you stop taking lamivudine tablets, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver.<span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">What are lamivudine tablets?<br><br></span>Lamivudine tablets are a prescription HIV-1 medicine used with other antiretroviral medicines to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults and children aged 3 months and older. HIV-1 is the virus that causes <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span> (AIDS).<br><br>Lamivudine tablets (used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) contain a higher dose of the same active ingredient (lamivudine) than is in the medicine EPIVIR-HBV tablets and oral solution (used to treat HBV). If you have both HIV-1 and HBV, you should not use EPIVIR-HBV to treat your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.<br><br>It is not known if lamivudine tablets are safe and effective in children under 3 months of age.<br><span class="Bold"><br>When used with other antiretroviral medicines to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, lamivudine tablets </span><span class="Bold">may help:</span></p>
<ul class="Disc">
<li>reduce the amount of HIV-1 in your blood. This is called â€œviral loadâ€?.</li>
<li>increase the number of CD4+ (T) cells in your blood, which help fight off other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
</ul>
<p>Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).<br><span class="Bold"><br>Lamivudine tablets do not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS. </span>You must keep taking HIV-1 medicines to control HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illnesses.<br><span class="Bold"><br>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others:</span></p>
<ul class="Disc">
<li>Do not share or re-use needles or other injection equipment.</li>
<li>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</li>
<li>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions, or blood.</li>
</ul>
<p>Ask your healthcare provider if you have any questions about how to prevent passing HIV to other people.<br><span class="Bold"><br>Who should not take lamivudine tablets?<br></span><span class="Bold"><br>Do not take lamivudine tablets </span>if you are allergic to lamivudine or any of the ingredients in lamivudine tablets. <span class="Bold">See â€œWhat are the ingredients in lamivudine tablets?â€?<br></span><span class="Bold"><br>Do not take lamivudine tablets if you also take:</span></p>
<ul class="Disc">
<li>other medicines that contain lamivudine (COMBIVIR<span class="Sup">Â®</span>, EPIVIR-HBV<span class="Sup">Â®</span>, EPZICOM<span class="Sup">Â®</span>, TRIZIVIR<span class="Sup">Â®</span>,TRIUMEQ<span class="Sup">Â®</span>)</li>
<li>medicines that contain emtricitabine (ATRIPLA<span class="Sup">Â®</span>, COMPLERA<span class="Sup">Â®</span>, EMTRIVA<span class="Sup">Â®</span>, STRIBILD<span class="Sup">Â®</span>, TRUVADA<span class="Sup">Â®</span>)</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking lamivudine tablets?<br></span><span class="Bold"><br>Before you take lamivudine tablets, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have or had liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>have kidney problems.</li>
<li>have any other medical condition.</li>
<li>are pregnant or plan to become pregnant. Taking lamivudine tablets during pregnancy has not been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Tell your healthcare provider if you become pregnant while taking lamivudine tablets.</li>
</ul>
<p><span class="Bold">Pregnancy Registry. </span>There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</p>
<ul class="Disc"><li>are breastfeeding or plan to breastfeed. <span class="Bold">Do not breastfeed if you take lamivudine tablets.</span><ul class="Disc">
<li>You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.</li>
<li>Talk to your healthcare provider about the best way to feed your baby.</li>
</ul>
</li></ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the counter medicines, vitamins, and herbal supplements. <span class="Bold">Keep a list of your medicines to show your healthcare provider and pharmacist. Do not start taking a new medicine without telling your healthcare provider. </span>Your healthcare provider can tell you if it is safe to takeÂ lamivudine tabletsÂ with other medicines.<br><span class="Bold"><br>How should I take lamivudine tablets?</span></p>
<ul class="Disc">
<li>Take lamivudine tablets exactly as your healthcare provider tells you.</li>
<li>Do not change your dose or stop taking lamivudine tablets without talking with your healthcare provider.</li>
<li>For children 3 months and older, your healthcare provider will prescribe a dose of lamivudine tablets based on your childâ€™s body weight.</li>
<li>Take lamivudine tablets by mouth, with or without food.</li>
<li>Tell your healthcare provider if you have trouble swallowing tablets. Lamivudine tablets also comes as a liquid (oral solution).</li>
<li>Do not skip doses. If you miss a dose of lamivudine tablets, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.</li>
<li>If you take too much lamivudine, call your healthcare provider or go to the nearest hospital emergency room right away. It is important to stay under your healthcare providerâ€™s care while taking lamivudine tablets.</li>
</ul>
<p><span class="Bold">What are the possible side effects of lamivudine tablets?<br></span><span class="Bold"><br>Lamivudine tablets can cause serious side effects. See â€œWhat is the most important information I should know about lamivudine tablets?â€?.</span></p>
<ul class="Disc">
<li>
<span class="Bold">Use with interferon and ribavirin-based treatment. </span>Worsening of liver disease that has sometimes led to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has happened in people infected with both HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus who are taking antiretroviral medicines, and are also being treated for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C with interferon with or without ribavirin. If you are taking lamivudine tablets and interferon with or without ribavirin, tell your healthcare provider if you have any new symptoms.</li>
<li>
<span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>). </span>Children may be at risk for developing <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> during treatment with lamivudine tablets if they:</li>
</ul>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last">
<td class="Lrule Rrule" valign="top"><ul class="Disc">
<li>have taken nucleoside analogue medicines in the past</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></li>
<li>have other risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></li>
</ul></td>
<td class="Rrule" valign="top"></td>
</tr></tbody></table>
<p><span class="Bold"><br>Call your healthcare provider right away if your child develops signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> including severe upper stomach-area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </span>Your healthcare provider may tell you to stop giving lamivudine tablets to your child if their symptoms and blood test results show that your child may have <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<ul class="Disc">
<li>
<span class="Bold">Changes in your immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>) </span>can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine.</li>
<li>
<span class="Bold">Changes in body fat can happen in people who take HIV-1 medicines. </span>These changes may include increased amount of fat in the upper back and neck (â€œbuffalo humpâ€?), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these problems are not known.</li>
</ul>
<p>The most common side effects of lamivudine tablets in adults include:</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last">
<td class="Lrule Rrule" valign="top"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>generally not feeling well</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
</ul></td>
<td class="Rrule" valign="top"><ul class="Disc">
<li>nasal signs and symptoms</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
</ul></td>
</tr></tbody></table>
<br><p>The most common side effects of lamivudine tablets in children include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.<br><br>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of lamivudine tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br><span class="Bold"><br>How should I store lamivudine tablets?</span></p>
<ul class="Disc"><li>Store lamivudine tablets at room temperature between 20Â° to 25Â°C (68Â° to 77Â°F)</li></ul>
<p><span class="Bold">Keep lamivudine tablets and all medicines out of the reach of children.<br></span><span class="Bold"><br>General information about the safe and effective use of lamivudine tablets.<br></span><br>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use lamivudine tablets for a condition for which it was not prescribed. Do not give lamivudine tablets to other people, even if they have the same symptoms that you have.Â They may harm them.<br><br>If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about lamivudine tablets that is written for health professionals.<br><br>For more information call Aurobindo Pharma USA, Inc. at 1-866-850-2876.<br><span class="Bold"><br>What are the ingredients in lamivudine tablets?<br></span><span class="Bold"><br>Active ingredient: </span>lamivudine<br><span class="Bold"><br>Inactive ingredients: </span>hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.<br><br>This Patient Information has been approved by the U.S. Food and Drug Administration.<br><br>The brands listed are trademarks of their respective owners and are not trademarks of the Aurobindo Pharma Limited. The makers of these brands are not affiliated with and do not endorse the Aurobindo Pharma Limited or its products.<br><br>Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.<br></span>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited<br></span>Unit-VII (SEZ)<br>Mahaboob Nagar (Dt)-509302<br>India<br><br>Revised: 07/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg (60 Tablets Bottle)</h1>
<br><p class="First"><span class="Bold">NDC 65862-552-60</span><br><span class="Bold">Lamivudine Tablets</span><br><span class="Bold">150Â mg</span><br><span class="Bold">Rx onlyÂ Â Â Â Â Â Â Â Â Â  60 Tablets</span><br><span class="Bold">AUROBINDO</span>Â </p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg (60 Tablet Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-fig3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton (6 x 10 Unit-dose)</h1>
<br><p class="First"><span class="Bold">NDC 65862-552-10</span><br><span class="Bold">Lamivudine Tablets 15</span><span class="Bold">0Â mg</span><br><span class="Bold">Rx onlyÂ Â Â Â Â Â Â Â Â Â Â 60 (6 x 10) Unit-doseÂ Tablets</span><br><span class="Bold">AUROBINDO</span></p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton (6 x 10 Unit-dose)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-fig4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_21"></a><a name="section-19"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 300 mg (30 Tablets Bottle)</h1>
<br><p class="First"><span class="Bold">NDC 65862-553-30</span><br><span class="Bold">Lamivudine Tablets</span><br><span class="Bold">300Â mg</span><br><span class="Bold">Rx onlyÂ Â Â Â Â Â Â Â Â Â  30 Tablets</span><br><span class="Bold">AUROBINDO</span>Â </p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 300 mg (30 Tablet Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-fig5.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_22"></a><a name="section-20"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 300 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton (3 x 10 Unit-dose)</h1>
<br><p class="First"><span class="Bold">NDC 65862-553-10</span><br><span class="Bold">Lamivudine Tablets 30</span><span class="Bold">0Â mg</span><br><span class="Bold">Rx onlyÂ Â Â Â Â Â Â Â Â Â Â 30 (3 x 10) Unit-doseÂ Tablets</span><br><span class="Bold">AUROBINDO</span></p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 300 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton (3 x 10 Unit-dose)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd55dd57-348c-4d78-b322-d1ae10279298&amp;name=lamivudine-fig6.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMIVUDINEÂ 		
					</strong><br><span class="contentTableReg">lamivudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65862-552</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">66;Y</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65862-552-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:65862-552-10</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202032</td>
<td class="formItem">11/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LAMIVUDINEÂ 		
					</strong><br><span class="contentTableReg">lamivudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65862-553</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">67;Y</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65862-553-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:65862-553-10</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202032</td>
<td class="formItem">11/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Aurobindo Pharma Limited
							(650082092)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">650381903</td>
<td class="formItem">ANALYSIS(65862-552, 65862-553), MANUFACTURE(65862-552, 65862-553)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917626</td>
<td class="formItem">API MANUFACTURE(65862-552, 65862-553)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ae55d252-8177-4447-ae3e-f1022d986507</div>
<div>Set id: bd55dd57-348c-4d78-b322-d1ae10279298</div>
<div>Version: 3</div>
<div>Effective Time: 20150731</div>
</div>
</div>Â <div class="DistributorName">Aurobindo Pharma Limited</div></p>
</body></html>
